Prevalence, Immunotherapy Use in Anorectal Mucosal Melanoma Found to Be Increasing
A retrospective study identified incidence of and treatment trends for anorectal mucosal melanoma tumors.
Melanoma
Incidence, Site of Pediatric Melanoma Different Among Male and Female Adolescents and Young Adults
Researchers in Colorado reviewed data on melanoma in pediatric patients 10 to 19 years, finding sex-specific differences in anatomic site and incidence of the disease.
Misdiagnosed Wart Highlights Importance of Obtaining Biopsy of Changing Skin Lesions
Patients who present with irregular or growing amelanocytic lesions on the acral surface of the hands or feet should undergo biopsy promptly.
Melanoma Treatment Regimens
View treatment regimens for melanoma, including guidance on options and dosing for a number of drugs including ipilimumab and dacarbazine.
Primary Histologic Subtype an Independent Predictor of Survival in Melanoma
A comparison study of the tumor molecular profiles of NM and SSM sought to explain the distinctly different prognoses among patients with either of these 2 histologic subtypes.
Sequence of Immunotherapy, Targeted Therapy, Radiation Therapy Influences Overall Survival in Melanoma Brain Metastases
Retrospective study investigated the effect sequence has on overall survival in patients with melanoma brain metastases treated with a combination of SRS, WBRT, immunotherapy, or targeted therapy.
Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
Results of a retrospective chart review of patients with BRAF-mutant metastatic melanoma receiving sequential treatment with immunotherapy and targeted therapy or vice versa are presented.
Number of Cutaneous Nevi Associated With Mortality Risk in Melanoma, Particularly for Men
An epidemiologic study shows that the number of cutaneous nevi may be a better independent predictor of melanoma death in men compared with women.
Melanoma Survival Varies Among U.S. States
The number of physicians in a state and melanoma incidence were factors in melanoma mortality, researchers found.
CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
Survival and progression-free survival were better with nivolumab alone or with ipilimumab vs ipilimumab alone for stage III or IV melanoma with known BRAFV600 mutation, according to results of this randomized study.
Next post in Melanoma
